Clinical Trial Detail

NCT ID NCT03210714
Title Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

pediatric ependymoma

Advanced Solid Tumor

neuroblastoma

pediatric osteosarcoma

hepatoblastoma

rhabdomyosarcoma

histiocytosis

neuroectodermal tumor

Ewing sarcoma

non-Hodgkin lymphoma

malignant glioma

childhood medulloblastoma

sarcoma

Therapies

Erdafitinib

Age Groups: adult child

Additional content available in CKB BOOST